16975-62-5

Basic information

• Product Name: 1,2-Propanediol, 3-(triphenylmethoxy)-, (R)-
• CAS NO: 16975-62-5
• Molecular Formula: C22H22O3
• Molecular Weight: 334.415
• Mol File: 16975-62-5.mol
• Article Data: 23

Chemical Properties

• CAS DataBase Reference: 1,2-Propanediol, 3-(triphenylmethoxy)-, (R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Propanediol, 3-(triphenylmethoxy)-, (R)-(16975-62-5)
• EPA Substance Registry System: 1,2-Propanediol, 3-(triphenylmethoxy)-, (R)-(16975-62-5)

Safety Data

• Hazardous Substances Data: 16975-62-5(Hazardous Substances Data)

Upstream product

• 76-83-5 trityl chloride 
• 56-81-5 glycerol 
• 55726-00-6 5-O-triphenylmethyl-L-arabinofuranose 
• 65291-30-7 (R)-(+)-trityl glycidyl ether 
• 26156-84-3 N-tritylpyridinium tetrafluoroborate 
• 252235-14-6 1,6,8-Trihydroxy-3-methyl-9,10-dioxo-9,10-dihydro-anthracene-2-carboxylic acid (S)-2-hydroxy-3-trityloxy-propyl ester 
• 16975-61-4 (R)-2,2-dimethyl-4-trityloximethyl-[1,3]dioxolane 
• 111247-96-2 methyl (2S)-2-hydroxy-3-(triphenylmethoxy)propanoate 
• 924896-93-5 D(R)-α-O-Trityl-β,γ-O-isopropyliden-glycerin 
• 65291-30-7 trityl glycidyl ether 
• 1235-22-9 allyl trityl ether 
• 5330-64-3 2,2-dimethyl-4-trityloxymethyl-[1,3]dioxolane 
• 121269-73-6 1-hydroxy-3-(triphenylmethoxy)propan-2-one 
• 5443-10-7 1,3-bis (trityloxy)propan-2-ol 

Downstream Products

• 250142-12-2 12-(2,2,2-Trichloro-1,1-dimethyl-ethoxycarbonylamino)-dodecanoic acid (S)-2-hydroxy-3-trityloxy-propyl ester 
• 22297-32-1 1-[(triphenylcarbinyl)oxy]-2,3-bis[(Z)-octadec-9-enyloxy]propane 
• 126272-25-1 1-dimethyl-tert-butylsilyloxy-3-trityloxypropan-2-ol 
• 1101186-16-6 1,2-di-O-(4-methoxybenzyl)-3-O-trityl-sn-glycerol 
• 13397-92-7 1,2-bis-elaidoyloxy-3-trityloxy-propane 
• 22202-46-6 (Z)-(S)-3-(trityloxy)propane-1,2-diyl dioleate 
• 1379802-63-7 (S)-1-(trityloxy)pent-3-yn-2-ol 
• 1379802-69-3 (R)-1-((4S,5R)-3-((2S,3R)-3-(tert-butyldiphenylsilyloxy)butan-2-yl)-4-methyl-4,5-dihydroisoxazol-5-yl)-2-(trityloxy)ethanol 
• 1132969-95-9 (R)-1-((4S,5R)-3-((2S,3S)-3-(tert-butyldiphenylsilyloxy)butan-2-yl)-4-methyl-4,5-dihydroisoxazol-5-yl)-2-(trityloxy)ethanol 
• 1132969-94-8 (S,Z)-1-(trityloxy)pent-3-en-2-ol 
• 16990-53-7 (S)-1-Z-Ala-3-O-benzyl-3-O-trityl-glycerin 
• 138493-74-0 Carbonic acid 2,2,2-trichloro-1,1-dimethyl-ethyl ester (R)-1-(4,4,4-trimethoxy-butoxymethyl)-2-trityloxy-ethyl ester 
• 140839-16-3 Octadecyl-carbamic acid 2-(5-methyl-tetrazol-2-yl)-3-trityloxy-propyl ester 
• 140712-03-4 Octadecyl-carbamic acid 2-(5-methyl-tetrazol-1-yl)-3-trityloxy-propyl ester 

Relevant articles and documents

Nucleic acid medicine delivery system and application thereof

The invention discloses a nucleic acid medicine delivery system and application thereof. The system consists of a neutral base lipid carrier and metal salt, wherein the structure of the neutral base lipid carrier is shown as a formula I. In addition, the delivery system provided by the invention also comprises metal salt. The experiment proves that through the existence of metal ion, the silent activity of the nucleic acid medicine can be effectively improved; the effective transportation of the nucleic acid medicine in the cells and in the body can be realized. The chemical modification methods such as D,L-isonucleoside modification, deoxyinosine modification, peptide conjugation modification and phosphorylation modification are jointly used for nucleic acid delivery system study; the advantages and rules of the nucleic acid delivery in a composite modification mode are sufficiently explored; the modification strategies are used in the nucleic acid medicine study. Study proves that the products obtained through chemical modification are more applicable to the system; in addition, the advantages of stable physicochemical properties, good bioactivity and good membrane permeability and the like are realized. The nucleic acid medicine delivery system provided by the invention has wide application prospects in the gene treatment field. The formula is shown in the description.

Total Synthesis of the Bis-silyl Ether of (+)-15-epi-Aetheramide A

Synthesis of the macrolactone depsipeptide aetheramide A was attempted by three different approaches. The first approach to form the macrolactone involving macrolactonization to form the C1-C21 bond and the second approach using a ring-closing metathesis (RCM) strategy to form the C10-C11 olefinic bond failed. The third approach starting from R-mandelic acid, involving the RCM reaction to install the C18-C19 ring junction, was successful in assembling the macrolactone.